Antares Pharma, Inc. (ATRS)
(Delayed Data from NSDQ)
$3.04 USD
+0.06 (2.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.04 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.04 USD
+0.06 (2.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.04 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
by Zacks Equity Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?
by Zacks Equity Research
Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of 10.71% and 1.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 6.25% and 3.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 3.25% and 1.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Q3 Earnings Match Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and -0.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Reports Next Week: What to Expect
by Zacks Equity Research
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Antares Pharma (ATRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Antares Pharma (ATRS) Meets Q1 Earnings Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Antares Pharma (ATRS) Q4 Earnings Lag Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Q3 Earnings Match Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
by Zacks Equity Research
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
AMAG Pharmaceuticals Focuses on Product Development & Buyouts
by Zacks Equity Research
We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.
AMAG Down Despite Positive Data on Makena Auto-Injector
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.